Free Trial
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Fulcrum Therapeutics logo
$6.88 -0.22 (-3.10%)
As of 04:00 PM Eastern

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Key Stats

Today's Range
$6.87
$7.27
50-Day Range
$3.46
$7.38
52-Week Range
$2.32
$10.13
Volume
1.02 million shs
Average Volume
919,134 shs
Market Capitalization
$371.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.29
Consensus Rating
Moderate Buy

Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

FULC MarketRank™: 

Fulcrum Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 927th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Fulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Fulcrum Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulcrum Therapeutics is -98.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulcrum Therapeutics is -98.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulcrum Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Fulcrum Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.59% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fulcrum Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Fulcrum Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.59% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Fulcrum Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for FULC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,520.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Fulcrum Therapeutics is held by insiders.

  • Percentage Held by Institutions

    89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulcrum Therapeutics' insider trading history.
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Headlines

FULC Stock Analysis - Frequently Asked Questions

Fulcrum Therapeutics' stock was trading at $4.70 at the start of the year. Since then, FULC shares have increased by 46.4% and is now trading at $6.88.
View the best growth stocks for 2025 here
.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) posted its quarterly earnings data on Thursday, May, 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01.
Read the conference call transcript
.

Fulcrum Therapeutics (FULC) raised $76 million in an IPO on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/01/2025
Today
6/30/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.29
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.73 million
Pretax Margin
-0.64%

Debt

Sales & Book Value

Annual Sales
$80 million
Price / Cash Flow
N/A
Book Value
$4.51 per share
Price / Book
1.53

Miscellaneous

Free Float
50,200,000
Market Cap
$371.38 million
Optionable
Optionable
Beta
2.40
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:FULC) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners